Clinical Trial Update: SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis [Phase 3]

View source ↗

Summary

A Phase 3 trial of SR34006 in patients who completed 6 months of treatment for symptomatic pulmonary embolism or deep vein thrombosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism

Drugs mentioned

• SR34006

Snippet

Sponsor: Sanofi | Conditions: Pulmonary Embolism, Deep Vein Thrombosis | Phase 3 | Status: COMPLETED